330 related articles for article (PubMed ID: 31759166)
81. JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling.
Schwemmers S; Will B; Waller CF; Abdulkarim K; Johansson P; Andreasson B; Pahl HL
Exp Hematol; 2007 Nov; 35(11):1695-703. PubMed ID: 17764814
[TBL] [Abstract][Full Text] [Related]
82. The Wnt/β-catenin signaling pathway is involved in regulating feather growth of embryonic chicks.
Xie WY; Chen MJ; Jiang SG; Yan HC; Wang XQ; Gao CQ
Poult Sci; 2020 May; 99(5):2315-2323. PubMed ID: 32359566
[TBL] [Abstract][Full Text] [Related]
83. Dissociation of the Jak kinase pathway from G-CSF receptor signaling in neutrophils.
Avalos BR; Parker JM; Ware DA; Hunter MG; Sibert KA; Druker BJ
Exp Hematol; 1997 Feb; 25(2):160-8. PubMed ID: 9015216
[TBL] [Abstract][Full Text] [Related]
84. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases.
Roskoski R
Pharmacol Res; 2016 Sep; 111():784-803. PubMed ID: 27473820
[TBL] [Abstract][Full Text] [Related]
85. Kinase-deficient forms of Jak1 and Tyk2 inhibit interferon alpha signaling in a dominant manner.
Krishnan K; Pine R; Krolewski JJ
Eur J Biochem; 1997 Jul; 247(1):298-305. PubMed ID: 9249040
[TBL] [Abstract][Full Text] [Related]
86. Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy.
Berthier CC; Zhang H; Schin M; Henger A; Nelson RG; Yee B; Boucherot A; Neusser MA; Cohen CD; Carter-Su C; Argetsinger LS; Rastaldi MP; Brosius FC; Kretzler M
Diabetes; 2009 Feb; 58(2):469-77. PubMed ID: 19017763
[TBL] [Abstract][Full Text] [Related]
87. A preliminary study of new single polymorphisms in the T helper type 17 pathway for psoriasis in the Korean population.
Kim SY; Hur MS; Choi BG; Kim MJ; Lee YW; Choe YB; Ahn KJ
Clin Exp Immunol; 2017 Feb; 187(2):251-258. PubMed ID: 27774581
[TBL] [Abstract][Full Text] [Related]
88. Cross-regulation of JAK and Src kinases.
Ingley E; Klinken SP
Growth Factors; 2006 Mar; 24(1):89-95. PubMed ID: 16393697
[TBL] [Abstract][Full Text] [Related]
89. Growth hormone receptor interaction with Jak proteins differs between tissues.
Hellgren G; Albertsson-Wikland K; Billig H; Carlsson LM; Carlsson B
J Interferon Cytokine Res; 2001 Feb; 21(2):75-83. PubMed ID: 11244571
[TBL] [Abstract][Full Text] [Related]
90. From buds to follicles: matrix metalloproteinases in developmental tissue remodeling during feather morphogenesis.
Jiang TX; Tuan TL; Wu P; Widelitz RB; Chuong CM
Differentiation; 2011 Jun; 81(5):307-14. PubMed ID: 21497985
[TBL] [Abstract][Full Text] [Related]
91. Discovery of selective TYK2 inhibitors: Design, synthesis, in vitro and in silico studies of promising hits with triazolopyrimidinone scaffold.
Istanbullu H; Coban G; Turunc E; Disel C; Debelec Butuner B
Bioorg Chem; 2024 Jul; 148():107430. PubMed ID: 38728909
[TBL] [Abstract][Full Text] [Related]
92. The JAK-inhibitor, JAB/SOCS-1 selectively inhibits cytokine-induced, but not v-Src induced JAK-STAT activation.
Iwamoto T; Senga T; Naito Y; Matsuda S; Miyake Y; Yoshimura A; Hamaguchi M
Oncogene; 2000 Sep; 19(41):4795-801. PubMed ID: 11032030
[TBL] [Abstract][Full Text] [Related]
93. Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.
Liu PC; Caulder E; Li J; Waeltz P; Margulis A; Wynn R; Becker-Pasha M; Li Y; Crowgey E; Hollis G; Haley P; Sparks RB; Combs AP; Rodgers JD; Burn TC; Vaddi K; Fridman JS
Clin Cancer Res; 2009 Nov; 15(22):6891-900. PubMed ID: 19887489
[TBL] [Abstract][Full Text] [Related]
94. Identification of a feather β-keratin gene exclusively expressed in pennaceous barbule cells of contour feathers in chicken.
Kowata K; Nakaoka M; Nishio K; Fukao A; Satoh A; Ogoshi M; Takahashi S; Tsudzuki M; Takeuchi S
Gene; 2014 May; 542(1):23-8. PubMed ID: 24631266
[TBL] [Abstract][Full Text] [Related]
95. Tyk2 mutation homologous to V617F Jak2 is not found in essential thrombocythaemia, although it induces constitutive signaling and growth factor independence.
Shide K; Shimoda K; Kamezaki K; Kakumitsu H; Kumano T; Numata A; Ishikawa F; Takenaka K; Yamamoto K; Matsuda T; Harada M
Leuk Res; 2007 Aug; 31(8):1077-84. PubMed ID: 17011030
[TBL] [Abstract][Full Text] [Related]
96. Janus kinase 2 activation by the platelet-activating factor receptor (PAFR): roles of Tyk2 and PAFR C terminus.
Lukashova V; Chen Z; Duhé RJ; Rola-Pleszczynski M; Stanková J
J Immunol; 2003 Oct; 171(7):3794-800. PubMed ID: 14500680
[TBL] [Abstract][Full Text] [Related]
97. A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways.
Chen CX; Zhang W; Qu S; Xia F; Zhu Y; Chen B
Cell Commun Signal; 2023 Oct; 21(1):287. PubMed ID: 37845748
[TBL] [Abstract][Full Text] [Related]
98. Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases.
Shen P; Wang Y; Jia X; Xu P; Qin L; Feng X; Li Z; Qiu Z
Eur J Med Chem; 2022 Sep; 239():114551. PubMed ID: 35749986
[TBL] [Abstract][Full Text] [Related]
99. The Stat3-activating Tyk2 V678F mutant does not up-regulate signaling through the type I interferon receptor but confers ligand hypersensitivity to a homodimeric receptor.
Gakovic M; Ragimbeau J; Francois V; Constantinescu SN; Pellegrini S
J Biol Chem; 2008 Jul; 283(27):18522-9. PubMed ID: 18456658
[TBL] [Abstract][Full Text] [Related]
100. JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors.
Nogueira M; Puig L; Torres T
Drugs; 2020 Mar; 80(4):341-352. PubMed ID: 32020553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
